Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141765 · ClinicalTrials.gov registry record · Phase 2
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00141765 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT00141765, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
Interventions
- PROCEDURE Myeloablative Chemotherapy
- PROCEDURE Stem Cell Rescue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1997-01 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141765
The ClinicalTrials.gov registry entry for NCT00141765 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Myeloablative Chemotherapy is the first listed.
NCT00141765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141765 about?
NCT00141765 is a clinical study titled "Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers". The purpose of this study is to determine whether very high dosages of chemotherapy will improve the chance of surviving cancer.
What is the current status of trial NCT00141765?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1997-01. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00141765?
The interventions under investigation include: Myeloablative Chemotherapy (PROCEDURE), Stem Cell Rescue (PROCEDURE).
Who is sponsoring clinical trial NCT00141765?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.